Skip to content

Trial · Interventional

CompletedPhase 4Registry data

Final Oocyte Maturation Via Administration of GnRH Agonists Followed By Luteal Support With hCG

NCTNCT01638026 (opens ClinicalTrials.gov in a new tab)Other idemc-0060-12-CTIL
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Completed
Phase
Phase 4
Enrollment
93 participants (actual)
Sponsor
HaEmek Medical Center, Israel · Other
Design
Allocation not applicable · Open label (no masking)
Countries
1 country

Israel

Start
Sept 2012
Primary completion
Jul 2017
Completion
Aug 2017
First posted
11 Jul 2012 (estimated)
Last update posted
29 Aug 2017
Conditions
Infertility

Timeline

1 trial · 1 completed

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
2012201320142015201620172018
  1. Ph 4

    Final Oocyte Maturation Via Administration of GnRH Agonists Followed By Luteal Support With hCG

    NCT01638026

    Sept 2012 to Aug 2017

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

Study Objectives: 1. To prove that the use of GnHR agonist for final oocyte maturation results in a higher percentage of mature oocytes than the use of hCG. 2. To show an advantage in women's satisfaction in the proposed protocol versus the standard antagonist protocol In the study group women will receive GnRH agonist for oocyte maturation, followed by ovum pick-up which will be performed 35 hours later. Embryo transfer will be performed 48-72 hours after ovum pick-up. Luteal support will include HCG 1500 IU. Blood samples for BHCG, progesterone and estradiol will be obtained 14 days after embryo transfer.

Interventions

  • TRIPTORELIN ACETATE, hCGDrug

Arms1

  • Experimental

    Gnrh agonist , hcg

    Gnrh agonist for final oocyte maturation, hcg for luteal support

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. fertilization rate

    Time frame · 4 weeks

Secondary outcomes(1)

  1. satisfaction, no. of oocyte, pregnancy rate, no. of embryos, quality of embryos

    Time frame · 4 weeks

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

Completed trials do not always post results.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies0

Studies that cite this trial.

No study cites this trial.

Eligibility

Who could join, as posted.

Sex
Female
Age
from 18 Years up to 45 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * patients who are eligible for in vitro fertilization using an antagonist protocol Exclusion Criteria: * patients diagnosed with hypogonadotrophic hypogonadism, sensitivity to any of the drugs used in the study A patient enrolled in the study who, as a result of ovarian stimulation, responds in a way that puts her in risk of developing ovarian hyperstimulation, will be ultimately excluded from the study.

PepBank is a research reference. Talk to a doctor before you use any peptide.